Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31434746 | 0.83 | NOTUM (0.49) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3968044 | 0.83 | NOTUM (0.72) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL1963850 | 0.81 | NOTUM (0.51) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL29241069 | 0.81 | NOTUM (0.51) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL2427499 | 0.81 | NOTUM (0.51) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL27163820 | 0.81 | CYP2C9 (0.47) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL28624057 | 0.81 | NOTUM (0.46) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL30336471 | 0.81 | NOTUM (0.46) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL1544128 | 0.81 | NOTUM (1.00) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3396472 | 0.81 | NOTUM (0.68) | NOTUMRAB9ATDP1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085347-A1 | IL4I1 INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-04-24 | — | — | WO | disclosed |
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | Recordati Industria Chimica e Farmacentica S.p.A. (IT) | 2022-09-13 | — | — | US | disclosed |
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2020-11-05 | — | — | US | disclosed |
| EP-3645521-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2020-05-06 | — | — | EP | disclosed |
| CN-111094269-A | Heterocyclylmethylene derivatives and their use as mGluR5 receptor modulators | 瑞蔻达蒂化学制药公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019002571-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2019-01-03 | — | — | WO | disclosed |
| EP-2470514-B1 | PSEUDO-DIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-07-12 | — | — | EP | disclosed |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) | 2012-12-06 | — | — | US | disclosed |
| EP-2470514-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023864-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2011-03-03 | — | — | WO | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| US-6251926-B1 | OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| CN-1300285-A | Hydroxyiminoalkanoic Acid Derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-06-20 | — | — | CN | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
| US-5041567-A | Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis | BEECHAM GROUP PLC (GB) | 1991-08-20 | — | — | US | disclosed |
| US-4812470-A | Antibacterial monic acid derivatives | BEECHAM GROUP P.L.C. (GB) | 1989-03-14 | — | — | US | disclosed |
| EP-0087953-B1 | ANTIBACTERIAL 1-NORMON-2-YL-HETEROCYCLIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
| EP-0087953-A2 | Antibacterial 1-normon-2-yl-heterocyclic compounds | BEECHAM GROUP PLC (GB) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | GRM5, GRIK5, GRM2 | NOTUM 1166/4885RAB9A 856/4885TDP1 1777/4885 |
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | GRM5, GRIK5, GRM2 | NOTUM 1166/4885RAB9A 856/4885TDP1 1777/4885 |
| US-20120309674-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | MMP3, MMP11, TIMP3 | NOTUM 1404/4885RAB9A 2015/4885TDP1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.